SOS1 and KRAS G12C Inhibitor Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly for solid tumors like pancreatic cancer, lung cancer, and colorectal cancer, face challenges in achieving durable responses and overcoming resistance mechanisms, with KRAS G12C inhibitors showing limited efficacy and rapid relapse in monotherapy.
Innovation Solution
Combining a SOS1 inhibitor with a KRAS G12C inhibitor to repress KRAS activation, shifting the equilibrium from the active GTP-KRAS form to the inactive GDP-KRAS form, thereby sensitizing tumors and inducing synergistic anti-proliferative effects and apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If KRAS G12C inhibitor monotherapy is used, then initial tumor response is achieved, but rapid relapse and resistance occur
Solution Approach 1:
The patent combines SOS1 inhibitor and KRAS G12C inhibitor into a dual-target therapy regimen. The SOS1 inhibitor blocks the GEF activity that activates KRAS, while the KRAS G12C inhibitor directly targets the mutant KRAS protein. This merging of two mechanisms of action prevents both primary resistance and adaptive resistance, achieving durable tumor responses without rapid relapse.
2Productivity
If KRAS G12C inhibitor is used alone, then some tumor cells are killed, but adaptive resistance mechanisms develop quickly
Solution Approach 1:
The SOS1 inhibitor is administered concurrently with the KRAS G12C inhibitor to preemptively block the activation pathway. By inhibiting SOS1 GEF activity before KRAS can be activated, the therapy prevents the adaptive resistance that would otherwise develop. This preliminary action on the upstream activator enhances and prolongs the anti-tumor efficacy of the KRAS G12C inhibitor.
3Reliability
If combination therapy is used, then response rate and durability improve, but treatment complexity increases
Solution Approach 1:
The combination therapy is segmented into two distinct molecular targets: SOS1 (upstream GEF) and KRAS G12C (downstream effector). This segmentation allows each inhibitor to be optimized for its specific target while working synergistically. The clear mechanistic division simplifies the rationale for combination use and facilitates clinical implementation despite the dual-agent complexity.
Data Source
AI summary
The invention describes anti-cancer therapies comprising using a SOS1 inhibitor in combination with a KRAS G12C inhibitor, each as described herein.